PPC
TVTX icon

Park Place Capital’s Travere Therapeutics TVTX Stock Holding History

Park Place Capital’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$862 Hold
29
– – ﹤0.01% 812
2025
Q4 		$1.11K Buy
+29
New +$943 ﹤0.01% 759

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Park Place Capital's TVTX Position: Q1 2026 in Review

Park Place Capital held its Travere Therapeutics (TVTX) position steady in Q1 2026 at 29 shares worth $862. The position accounts for ﹤0.01% of the portfolio, ranked #812.

Park Place Capital first reported a position in TVTX in Q4 2025 and has held it in 2 quarters since. The position peaked at $1.11K in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Park Place Capital held 29 shares of Travere Therapeutics worth $862 as of Q1 2026.
  • Park Place Capital left its Travere Therapeutics share count unchanged in Q1 2026.
  • Travere Therapeutics made up ﹤0.01% of Park Place Capital's portfolio in Q1 2026, its #812 holding.
  • Park Place Capital first reported a position in Travere Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Park Place Capital's Travere Therapeutics position peaked at $1.11K in Q4 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Park Place Capital's 13F filing for Q1 2026, filed 9 Apr 2026.